Biogen Stock: Will The $8 Billion Opportunity Materialize For Alzheimer’s Drugs?
Biogen inventory popped Thursday after an analyst steered the biotech firm may reap $8 billion in gross sales of its Alzheimer's therapies — assuming every part traces up correctly. X ...
